Status and phase
Conditions
Treatments
About
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.
Full description
Fragile X Syndrome is a genetically determined neurological disorder in which affected individuals are intellectually handicapped to varying degrees and display a variety of associated psychiatric symptoms. Clinically, Fragile X Syndrome is characterized by intellectual handicap, hyperactivity and attentional problems, autism spectrum symptoms, emotional lability and epilepsy. The epilepsy seen in Fragile X Syndrome is most commonly present in childhood, but then gradually remits towards adulthood. Physical features such as prominent ears and jaw, and hyper-extensibility of joints are frequently present but are not diagnostic. Intellectual handicap is the most common feature defining the phenotype. Treatment for the disorder is symptomatic - focusing on the management of symptoms - and supportive, requiring a multidisciplinary approach.
This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult males with Fragile X Syndrome. The study also will also investigate measures of efficacy during treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Fragile X Syndrome with a molecular genetic confirmation of the full FMR1 mutation.
Results from previously completed testing are acceptable with written documentation of the genetic results.
Results from PCR or Southern blot tests are acceptable
Results from cytogenetic testing are not acceptable but subject may be eligible if molecular genetic testing is redone.
A full mutation with mosaicism is allowed if:
The following results would not meet criteria:
Males, aged 12-45 years
Subjects with a Clinical Global Impression - Severity (CGI-S) score of 4 or greater at Screening
Subjects with a total score of 30 or greater on the Aberrant Behavior Checklist (ABC) at Screening.
Current treatment with no more than 3 psychotropic medications. This includes medications used to treat problems with sleep onset and sleep continuity. Melatonin for difficulties with sleep onset is permissible and is excepted from the count of psychotropic medications. Similarly, anti-epileptic medications are permitted and are not denoted as "psychotropic medications" if they are used for treatment of seizures. Use of anti-epileptics for other indications such as the treatment of mood disorders counts towards the limit of permitted medications. Concurrent use of omega-3 fatty acids is also permissible and does not count towards the allowed number of concomitant psychotropic medications. A complete list of permitted concomitant psychotropic medications can be found in Appendix A.
Concomitant medications for chronic medical conditions are permissible. Examples of chronic medical conditions include gastroesophageal reflux disease (GERD) and asthma. Every effort should be made to keep the doses and dosing regimens of these medications stable in the 4 weeks preceding Screening and during the period between Screening and the commencement of study medication.
Behavioral treatments excluding psychotherapy (see exclusion criteria) must be stable for 4 weeks prior to Screening and must remain stable during the period between Screening and the commencement of study medication
a. For each enrollee, every effort should be made to maintain stable regimens of allowed concomitant medications and allowed behavioral therapies from the time of commencement of single-blind study medication until the last study assessment.
Sufficient expressive language capabilities to complete the Expressive Language Sampling Task.
Individuals with a history of seizures should have a stable pattern of seizure activity in the 3 months preceding Screening.
Exclusion criteria
Treatment within the two weeks prior to Screening with monoamine (MAO) inhibitors, lithium, minocycline, acamprosate, racemic baclofen, investigational metabotropic glutamate receptor subtype 5 (mGluR5) medications, d-cycloserine, oxytocin, carbetocin, tricyclic antidepressants and bupropion.
Patients planning to commence psychotherapy, including cognitive behavior therapy (CBT), during the period of the study or those who had begun psychotherapy, including CBT, within 6 weeks prior to Screening.
History of, or current, cardiovascular, renal, hepatic, respiratory and/or gastrointestinal disease, which may interfere with the absorption, distribution, metabolism or excretion of the study medication, or which may interfere with the interpretation of the safety/tolerability or efficacy of the study medication.
History of, or current cerebrovascular disease or clinically significant brain trauma.
History of, or current clinically significant endocrine disorder, e.g. hypo or hyperthyroidism, or diabetes.
History of, or current malignancy.
Current major depressive disorder (patients have to be free of the most recent episode for 3 months prior to enrollment).
History of a DSM-5-defined substance use disorder in the 3 months prior to Screening.
Clinically significant abnormalities in safety laboratory tests, vital signs or ECG, as measured at Screening.
QT/QTcF Exclusions (any of the following):
Patients with significant hearing and/or visual impairments that may affect their ability to complete the test procedures.
Current treatment with insulin
Hgb A1C values outside of the normal reference range at Screening
Current or past treatment with insulin like growth factor IGF-1
Current or past treatment with growth hormone
Enrollment in another clinical trial within the 30 days preceding Screening
Previously randomized in this clinical trial
Allergy to strawberry
Primary purpose
Allocation
Interventional model
Masking
72 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal